Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrathecal Rituximab in CNS Lymphoid Malignancies
NCT01596127Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2013
- Primary completion
- Mar 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in lymphoid malignancies, sponsored by University of Texas MD Anderson Cancer Center. Started Jan 2013; status: terminated.
02
Drugs
rituximab
03
Conditions
lymphoid malignancies
Beyond the preview
Go deeper on NCT01596127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01596127.